Business Wire

MHPS Successfully Tests Large-Scale High-Efficiency Gas Turbine Fueled by 30% Hydrogen Mix

Jaa

A large-scale gas turbine for use in power generation under development by Mitsubishi Hitachi Power Systems, Ltd. (MHPS) has successfully passed a firing test using a 30% hydrogen fuel mix*1. The test results confirmed that by using MHPS’s proprietary burner, which was newly developed to burn hydrogen, stable combustion can be attained even when hydrogen is mixed with natural gas. Using a 30% hydrogen mixture, a reduction in carbon dioxide (CO2) emissions of 10% was achieved, compared to natural-gas-fired power generation.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180125005516/en/

Actual-pressure combustion testing facilities that carried out the hydrogen-mixed firing test (Photo ...

Actual-pressure combustion testing facilities that carried out the hydrogen-mixed firing test (Photo: Business Wire)

The hydrogen-mixed firing test was carried out at MHPS’s Takasago Works, using actual-pressure combustion testing facilities, as part of a project of Japan’s New Energy and Industrial Technology Development Organization (NEDO) aimed at developing technologies for realizing a “hydrogen society.” In a hydrogen society, broad use is made of hydrogen—a clean, carbon-free energy that releases no greenhouse gases.

The firing test conditions called for a turbine inlet temperature of 1,600℃, equivalent to 700 megawatts (MW) of output, using the premix combustor of the natural-gas-fired J-Series gas turbines, which provides power generation efficiency above 63%. With a hydrogen mix of 30%, stable combustion was demonstrated while satisfying operable threshold values pertaining to nitrogen oxide (NOx) emissions, combustion oscillation, etc.*2

The stable hydrogen-mixed firing technology applied in the large-scale gas turbine uses MHPS’s proprietary dry low-NOx (DLN) combustor developed for this project as an improved version of the Company’s natural-gas-fired combustors. The combustion method is premixing, a field in which MHPS has abundant experience through its use of DLN combustors. The combustor’s fuel nozzle creates a rotational airflow that enables the formation of a more uniform premixed gas, leading to low NOx. Other than the combustor, the equipment currently in place can be used without modification, thereby curbing the potential costs of converting a natural-gas-fired power plant to a hydrogen plant.

In Japan, under the leadership of the Ministry of Economy, Trade and Industry and the Cabinet Office, efforts are underway to develop hydrogen as one of the nation’s core energies. Research and development of gas turbines fueled by hydrogen currently focuses on small and medium-size gas turbines for small-scale thermal power plants suited to distributed power generation or area cogeneration. Now, with successful testing toward use of hydrogen fuel in a large-scale gas turbine for large-scale thermal power plants, expectations are focusing on the new technology making a major contribution to easing the burden on the global environment during power generation. It marks the first step toward realizing a CO2-free hydrogen society, a key strategy set last December at the second meeting of Japan’s Ministerial Council on Renewable Energy, Hydrogen and Related Issues.

Following this successful test, MHPS will accelerate the development of hydrogen-fueled gas turbines and encourage hydrogen use by thermal power plant operators. Mitsubishi Heavy Industries Group is also a leader in CO2 capture and storage (CCS) technology, which is indispensable for supplying carbon-free hydrogen. By linking these technologies, the Group is poised to lead the development of an international supply chain spanning hydrogen supply, transport and storage, thereby contributing to realization of a hydrogen society.

 

Notes

   

*1:

 

The ratio of hydrogen content indicates volume ratio.

*2:

The NEDO project actually targets a 20% hydrogen mix. For testing purposes, a 30% mixture was used in order to secure ample tolerance for use in actual power plants. Going forward, efforts will continue to focus on improving mixed-combustion technology.

 

About Mitsubishi Hitachi Power Systems, Ltd.

Mitsubishi Hitachi Power Systems, Ltd. (MHPS), headquartered in Yokohama, Japan, is a joint venture formed in February 2014 by Mitsubishi Heavy Industries, Ltd. and Hitachi, Ltd. integrating their operations in thermal power generation systems and other related businesses. MHPS today ranks among the world’s leading suppliers of equipment and services to the power generation market, backed by 100 billion yen in capital and approximately 20,000 employees worldwide. The Company’s products include GTCC (gas turbine combined-cycle) and IGCC (integrated coal gasification combined-cycle) power plants, conventional gas/coal/oil-fired (thermal) power plants, boilers, generators, gas and steam turbines, geothermal power plants, AQCS (air quality control systems), power plant peripheral equipment and solid-oxide fuel cells (SOFC). For more information, please visit the Company's website at https://www.mhps.com/en/index.html

Contact information

Mitsubishi Heavy Industries, Ltd.
Joseph Hood, +81-(0)3-6716-2168
PR Manager
mhi-pr@mhi.co.jp
Fax: +81-(0)3-6716-5860

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

CES Asia: Innovation at the Speed of 5G15.6.2018 17:59Tiedote

CES Asia® 2018 wrapped today with the rapid pace of global innovation front and center over the show’s three day duration. The next stage of technology advancements were showcased across vehicle tech, robotics, artificial intelligence (AI), virtual and augmented reality, digital health and more. The event, 24 percent larger than last year in terms of footprint, cemented itself as the place to fully experience how the pace of technology is accelerating globally. CES Asia, the premier event for tech innovation in the Asian marketplace, will return to Shanghai, China, June 11-13, 2019. “5G and AI are igniting growth across the entire tech ecosystem changing the way we interact with technology and the world around us,” said Gary Shapiro, president and CEO, Consumer Technology Association (CTA)™. “It’s incredible to see technology refining and reinventing itself at such a fast pace. Just six months ago we were at CES with life-altering tech all around us. This week, I saw that technology re

bluebird bio Presents New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin™ Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia at Annual Congress of the European Hematology Association15.6.2018 13:00Tiedote

bluebird bio, Inc. (Nasdaq: BLUE) announced that new data from the completed Phase 1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase 3 Northstar-2 (HGB-207) multicenter clinical study of LentiGlobin™ investigational gene therapy in patients with TDT and non-β0/β0 genotypes, will be presented in an oral session on June 16 at the 23rd Annual Congress of the European Hematology Association by Franco Locatelli, M.D., Ph.D., of the IRCCS Ospedale Pediatrico Bambino Gesù of Rome, Italy. “The maturing data from HGB-204 and HGB-207 suggest that one-time treatment with LentiGlobin may address the underlying genetic cause of TDT. With our refined manufacturing process, the majority of patients with TDT and non-β0/β0 genotypes are transfusion-free and producing total hemoglobin at normal or near-normal levels,” said David Davidson, M.D., chief medical officer, bluebird bio. “We are on track to submit a m

bluebird bio Announces New Interim Data from Phase 1 (HGB-206) Study of LentiGlobin™ Gene Therapy in Patients with Severe Sickle Cell Disease at Annual Congress of the European Hematology Association15.6.2018 13:00Tiedote

bluebird bio, Inc. (Nasdaq: BLUE) today announced new interim data from the ongoing HGB-206 Phase 1 multicenter clinical study of LentiGlobin investigational gene therapy in patients with severe sickle cell disease (SCD) will be presented in an oral presentation on Saturday, June 16 at the 23rd Congress of the European Hematology Association (EHA) by Julie Kanter, M.D., Medical University of South Carolina, Charleston, South Carolina. “The consistent production of increased amounts of anti-sickling HbAT87Q in the Group C patients reflects the substantial positive impact of the changes introduced with the amended HGB-206 study protocol and refined manufacturing process. All four Group C patients with greater than or equal to three months follow-up are making over 30 percent anti-sickling HbAT87Q. The first patient treated, now with six months of follow-up, is producing over 60 percent anti-sickling HbAT87Q with a normal total hemoglobin level of 14.2 g/dL,” said David Davidson, M.D., ch

AGP Group Announces the Acquisition of Soliver NV in Belgium, Representing a Key Step towards Becoming the Premier Global Leader in Designing and Manufacturing High-Tech Automotive Glazing15.6.2018 12:00Tiedote

AGP, a high-tech specialty glass designer and manufacturer, has announced today the acquisition of Soliver NV, a European automotive glazing manufacturer with over 65 years of solid product and brand reputation. Soliver offers high-quality tempered and laminated glazing for high-end automobiles, as well as windshield solutions for trucks. AGP’s glazing heritage started in Berlin, with the Mannheim family´s first glass company. After 100 years and a clear vision to become a leader in specialty glass, AGP’s core eGlass technologies have responded to the rising demand in electrification, connectivity, shared mobility and autonomous driving, acting as an enabler of future mobility trends. The integration of Soliver into the AGP Group will strengthen the AGP eGlass value proposition and will be a game changer in a fast-evolving industry. “We are very excited to build upon Soliver’s great experience and track-record to take high-tech glazing to the next level, enabling our customer’s product

Rivoli Group announces completion of its new international corporate strategy15.6.2018 10:00Tiedote

Rivoli Group AG completes its comprehensive operational restructuring process and acts with a new presence in the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180615005085/en/ Rivoli Group Announces Completion of Its New International Corporate Strategy (Photo: Business Wire) The Swiss based Rivoli Group AG has now completed the comprehensive restructuring process as part of the international realignment of its corporate strategy. After an intensive evaluation of the situation, the available resources and existing market potential, the Chairman of the Board of Directors Mr. Mourad Malloul, the management team and an international advisory committee coordinated the strategy together. "This is the beginning of a crucial new chapter for the Rivoli Group," the President and CEO of Rivoli Group AG said. The measure aims to strengthen the competitive advantages within the company group, to adjust their service offerings

PMI’s Latest Clinical Results: Findings Add to Extensive Evidence Package on Risk Reduction15.6.2018 10:00Tiedote

Philip Morris International (PMI) (NYSE:PM) announces today the positive results from a new clinical study on IQOS, the company’s most advanced smoke-free product. The Exposure Response Study (ERS) measured the biological response of people who switch to IQOS for six months compared with continued smoking. The study met its primary objective, demonstrating that after six months, eight measures of biological response (the primary clinical risk endpoints) improved in those who switched to IQOS. PMI’s Scientific Assessment Program has rigorously tested IQOS over more than 7 years and supports that switching to our most advanced smoke-free product is likely to present less risk of harm than continuing to use cigarettes. Numerous aerosol chemistry and physics measurements demonstrate that IQOS aerosol contains an average of 90-95% lower levels of harmful constituents. Our results support that these reduced emissions translate to reduced toxicity in the laboratory and to reduced exposure in

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme